DPD 207
Alternative Names: DPD-207Latest Information Update: 28 Jul 2024
At a glance
- Originator Destiny Pharma
- Class Antibacterials; Metalloporphyrins
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Bacterial infections; Mycoses
Most Recent Events
- 28 Jul 2024 No recent reports of development identified for preclinical development in Mycoses in China
- 28 Mar 2022 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom (IV)
- 28 Mar 2022 No recent reports of development identified for preclinical development in Bacterial-infections in United Kingdom (PO)